Bladder Tumour Marker (NMP22), Urine

Transitional cell carcinoma of the bladder (TCC) is the second most common malignancy of the urinary tract. More than 70% of treated tumours recur, and 30% of recurrent tumours progress. Currently, pathologic staging and grading are valuable prognostic factors for detecting and monitoring +TCC. Urinalysis, cystoscopy, and cytology are either invasive or lack sensitivity and specificity. The sensitivity of cystoscopy has been established at around 70% however, cystoscopy is invasive. Urine cytology has a specificity of > 90% however, the sensitivity is moderate ranging between 20-40%.

NMP22 is recognised as a urothelial-specific cancer marker. Clinical research has demonstrated significant differences in NMP22 concentrations in urine of healthy volunteers compared with concentrations in patients with active TCC. The sensitivity of the rapid tests was found to be 63.2% for grade 1, 88.2% for grade 2, and 95.0% for grade 3 TCC.

10 ml Urine Room Temperature

Bladder washing (barbotage) should not be used. State patient's age, sex, and clinical history.

By Report